Kalkine Media ASX Share Market News & Research
Watchlist Sign Up/Login
Kalkine Media ASX Share Market News & Research

Pfizer-BioNTech Vaccine Likely To Be Available by December-end

1 min read | November 20, 2020 10:01 AM EST | By Team Kalkine Media
Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Recent News

thumbnail

FirstService (TSX:FSV) Results Reveal Mixed Business Performance Trend...

thumbnail

Three Canadian Dividend Stocks With Yields Above Five Percent

thumbnail

Why Is Tidewater Midstream (TSX:TWM) Drawing Attention After Scotiaban...

thumbnail

Suncor Energy (TSX:SU) Remains A Key Name In Canada's Energy Sector

Make Kalkine Media
My Trusted Source

Google Source

 

  • Pfizer (NYSE:PFE) and BioNTech (Nasdaq:BNTX) are expected to submit the approval request for their COVID-19 vaccine candidate BNT162b2 to the Food and Drug Administration (FDA) on Friday, November 20 for urgent use in the US.
  • The two companies, which worked on the vaccine in partnership, has also begun approval request procedures with other countries, including Australia, Canada, Europe, Japan, and the UK.
  • Based on current estimates, the companies are expected to supply up to 50 million shots globally in 2020 and up to 1.3 billion shots by the end of 2021.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

CA_Premium_Article

Sponsored Articles

1

Graphite One (TSXV:GPH) Highlights Strategic Alignment with U.S. Criti...

2

Canasil Resources (TSX-V: CLZ) Secures Shareholder Approval for Canadi...

3

ESGold (CSE:ESAU) Reaches New Development Milestones at Montauban Gold...

4

Minaurum Silver (TSXV: MGG) Builds Momentum at Alamos with Resource an...

5

Kane Biotech (TSXV: KNE) Strengthens Financial Position to Support U.S...

Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.